← All trials
NCT06439524
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2024
- Primary completion
- Feb 15, 2026
- Completion date
- Aug 15, 2026
- First posted
- Jun 3, 2024
- Last posted
- Aug 21, 2024
- Enrollment
- 110
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Main Line HealthLead sponsor
- Main Line HealthOfficial
- PfizerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.